A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population

PURPOSE: Biosimilar IFX (CT-P13) received marketing approval in Turkey for treatment of rheumatologic diseases, including ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis. Population data on real-world treatment patterns of CT-P1...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazici, Yusuf, Xie, Lin, Ogbomo, Adesuwa, Ellis, Lorie A, Goyal, Kavitha, Teeple, Amanda, Mutlu, Ece A, Simsek, Ismail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174299/
https://www.ncbi.nlm.nih.gov/pubmed/30323555
http://dx.doi.org/10.2147/BTT.S172241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174299/
https://www.ncbi.nlm.nih.gov/pubmed/30323555
http://dx.doi.org/10.2147/BTT.S172241

Ejemplares similares